CLGNHealthcare · BiotechnologyCLGN Stock Forecast: CollPlant Biotechnologies Ltd. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 33 of 100 as at 1 Aug 2026 — in the lower half.
CLGN stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores CollPlant Biotechnologies Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (95): Smaller than most of the companies we track.
Value (6): The shares cost a lot relative to the profits and assets behind them.
The rank is the raw material. Whether the rules would actually own CollPlant Biotechnologies Ltd. — and when they’d sell — is the membership.
CLGN stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on CLGN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 6 Feb 2026 | D. Boral Capital | Downgrade | Hold | — |
| 28 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 20 Oct 2025 | D. Boral Capital | Maintains | Buy | — |
| 16 Sept 2025 | D. Boral Capital | Maintains | Buy | — |
| 21 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 30 May 2025 | D. Boral Capital | Maintains | Buy | — |
| 28 May 2025 | D. Boral Capital | Maintains | Buy | — |
| 27 Mar 2025 | D. Boral Capital | Maintains | Buy | — |
| 12 Feb 2025 | D. Boral Capital | Maintains | Buy | — |
| 4 Feb 2025 | D. Boral Capital | Maintains | Buy | — |
| 29 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 Nov 2024 | D. Boral Capital | Maintains | Buy | — |
| 21 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Aug 2024 | EF Hutton | Maintains | Buy | — |
| 5 Aug 2024 | EF Hutton | Initiates | Buy | — |
| 30 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 Apr 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 Nov 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
CLGN analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
CollPlant Biotechnologies Ltd. (CLGN) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.3×
- Price / sales
- 15.5×
- Price / book
- 0.9×
- EV / EBITDA
- −0.2×
Cheaper than 78% of US stocks
Cheaper than 11% of US stocks
Cheaper than 74% of US stocks
Cheaper than 63% of US stocks
- Revenue growth (YoY)
- −96.4%
- Earnings growth (YoY)
- —
- Gross margin
- −332.9%
- Operating margin
- −4267.1%
- Net margin
- 64.8%
Higher than 2% of US stocks
Higher than 1% of US stocks
Higher than 3% of US stocks
Higher than 97% of US stocks
- Return on equity
- −152.0%
- Return on assets
- −61.3%
- Dividend yield
- —
Higher than 9% of US stocks
Higher than 6% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
CLGN vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CLGN appears on the weeks it earns a place.
Frequently asked questions about CLGN stock
Is CLGN stock a buy right now?
Of the 1 analysts covering CollPlant Biotechnologies Ltd., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CollPlant Biotechnologies Ltd. 33 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank CLGN?
As at 1 Aug 2026, CollPlant Biotechnologies Ltd. ranks 33 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (95 of 100).
What is the CLGN stock forecast for 2030?
No analyst covering CollPlant Biotechnologies Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CLGN are extrapolating price history, which says nothing about the business.
How has CLGN stock performed over the past year?
CollPlant Biotechnologies Ltd. returned -86.1% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does CollPlant Biotechnologies Ltd. do?
CollPlant Biotechnologies Ltd. is a pioneering biomedical company that specializes in regenerative medicine and tissue engineering.
About CollPlant Biotechnologies Ltd.
CollPlant Biotechnologies Ltd. is a pioneering biomedical company that specializes in regenerative medicine and tissue engineering. At the heart of its offerings is the development of innovative human tissue products using plant-based recombinant collagen. This unique bioengineering approach is significant as it provides an alternative to traditional animal-derived collagen, enhancing safety and biocompatibility in medical applications. CollPlant's primary focus areas include the development of bioinks for 3D bioprinting and the creation of scaffolds for tissue repair and regeneration, particularly in the fields of orthopedics and wound care. Headquartered in Israel, the company has made a notable impact in the biotechnology sector, offering solutions that promise to revolutionize regenerative medicine. CollPlant's contributions are crucial in advancing medical treatments with applications that extend across cosmetic surgery, orthopedics, and chronic wound care, marking its role as a significant player in the global healthcare and life sciences markets.
CEO Mr. Yehiel Tal · 39 employees · Israel · https://collplant.com